UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Oral Hedgehog Inhibitor, Vismodegib, for Locally Advanced Periorbital and Orbital Basal Cell Carcinoma

Ophthalmology (Rochester, Minn.), 2024-07

2024

Volltextzugriff (PDF)

The importance of caregivers for patients with advanced basal cell carcinoma treated with hedgehog-pathway inhibitors: an observational prospective study

EJD. European journal of dermatology, 2024-02, Vol.34 (1), p.68-72

2024

Volltextzugriff (PDF)

Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors

Critical reviews in oncology/hematology, 2023-09, Vol.189, p.104066-104066, Article 104066

2023

Volltextzugriff (PDF)

Strategies to target the Hedgehog signaling pathway for cancer therapy

Medicinal research reviews, 2018-05, Vol.38 (3), p.870-913

2018

Volltextzugriff (PDF)

Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness

Dermatology (Basel), 2023-12, Vol.239 (6), p.868-876

2023

Volltextzugriff (PDF)

Oral smoothened inhibitors for Gorlin syndrome: A clinical review

Journal of the American Academy of Dermatology, 2024-10, Vol.91 (4), p.706-711

2024

Volltextzugriff (PDF)

Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma

Dermatology reports, 2024-07

2024

Volltextzugriff (PDF)

Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma

Journal of Immunotherapy and Precision Oncology, 2024-08, Vol.7 (3), p.201-204

2024

Volltextzugriff (PDF)

Beyond cyclopamine: Targeting Hedgehog signaling for cancer intervention

Archives of biochemistry and biophysics, 2024-04, Vol.754, p.109952, Article 109952

2024

Volltextzugriff (PDF)

Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma

Oncotarget, 2021-12, Vol.12 (26), p.2531-2540

2021

Volltextzugriff (PDF)

Hedgehog signaling inhibitors in solid and hematological cancers

Cancer treatment reviews, 2019-06, Vol.76, p.41-50

2019

Volltextzugriff (PDF)

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

BMC cancer, 2017-05, Vol.17 (1), p.332-332, Article 332

2017

Volltextzugriff (PDF)

Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: a single-center study and a new dedicated therapeutic protocol

Dermatology reports, 2021-11, Vol.13 (3)

2021

Volltextzugriff (PDF)

The use of hedgehog antagonists in cancer therapy: a comparison of clinical outcomes and gene expression analyses

Cancer biology & therapy, 2020-10, Vol.21 (10), p.873-883

2020

Volltextzugriff (PDF)

Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?

Expert opinion on pharmacotherapy, 2022-04, Vol.23 (6), p.739-740

2022

Volltextzugriff (PDF)

Basal Cell Carcinoma: A Comprehensive Review

International journal of molecular sciences, 2020-08, Vol.21 (15), p.5572

2020

Volltextzugriff (PDF)

Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation

Expert opinion on drug safety, 2023-07, Vol.22 (7), p.525-531

2023

Volltextzugriff (PDF)

Characterization and Management of Hedgehog Pathway Inhibitor‐Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

The oncologist (Dayton, Ohio), 2016-10, Vol.21 (10), p.1218-1229

2016

Volltextzugriff (PDF)

Expert opinion on sonidegib efficacy, safety and tolerability

Expert opinion on drug safety, 2021-08, Vol.20 (8), p.877-882

2021

Volltextzugriff (PDF)

Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study

EJD. European journal of dermatology, 2023-06, Vol.33 (3), p.280-286

2023

Volltextzugriff (PDF)

Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis

Acta neuropathologica communications, 2019-07, Vol.7 (1), p.123-123, Article 123

2019

Volltextzugriff (PDF)

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.113-125.e5

2016

Volltextzugriff (PDF)

Sonidegib for the Treatment of Advanced Basal Cell Carcinoma

Frontiers in oncology, 2020-10, Vol.10, p.582866-582866

2020

Volltextzugriff (PDF)

Study on hydrolytic, oxidative and photolytic degradation behaviour of anticancer drug sonidegib: Characterization of the products by UHPLC-Q-TOF-MS/MS, 2D NMR and in silico toxicity assessment

Journal of environmental chemical engineering, 2024-10, Vol.12 (5), p.114111, Article 114111

2024

Volltextzugriff (PDF)

Clinical clearance of complex basal cell carcinoma in patients receiving sonidegib: A case series

Dermatologic therapy, 2022-02, Vol.35 (2), p.e15217-n/a

2022

Volltextzugriff (PDF)

1 – 25 von 163

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(136)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Sonidegib
(157)
Science & Technology
(117)
Life Sciences & Biomedicine
(116)
Vismodegib
(85)
Basal Cell Carcinoma
(81)
Humans
(56)
Oncology
(47)
Skin Cancer
(42)
Dermatology
(38)
Carcinoma, Basal Cell - Drug Therapy
(35)
Pharmacology & Pharmacy
(31)
Skin Neoplasms - Drug Therapy
(31)
Cancer
(26)
Tumors
(26)
Skin Neoplasms - Pathology
(25)
Carcinoma, Basal Cell - Pathology
(24)
Patients
(22)
Review
(22)
Hedgehog Proteins - Antagonists & Inhibitors
(21)
Hedgehog Proteins - Metabolism
(21)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Oral Hedgehog Inhibitor, Vismodegib, for Locally Advanced Periorbital and Orbital Basal Cell Carcinoma

The importance of caregivers for patients with advanced basal cell carcinoma treated with hedgehog-pathway inhibitors: an observational prospective study

Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors

Strategies to target the Hedgehog signaling pathway for cancer therapy

Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness

Oral smoothened inhibitors for Gorlin syndrome: A clinical review

Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma

Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma

Beyond cyclopamine: Targeting Hedgehog signaling for cancer intervention

Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma

Hedgehog signaling inhibitors in solid and hematological cancers

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: a single-center study and a new dedicated therapeutic protocol

The use of hedgehog antagonists in cancer therapy: a comparison of clinical outcomes and gene expression analyses

Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?

Basal Cell Carcinoma: A Comprehensive Review

Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation

Characterization and Management of Hedgehog Pathway Inhibitor‐Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

Expert opinion on sonidegib efficacy, safety and tolerability

Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study

Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma

Sonidegib for the Treatment of Advanced Basal Cell Carcinoma

Study on hydrolytic, oxidative and photolytic degradation behaviour of anticancer drug sonidegib: Characterization of the products by UHPLC-Q-TOF-MS/MS, 2D NMR and in silico toxicity assessment

Clinical clearance of complex basal cell carcinoma in patients receiving sonidegib: A case series

Suchergebnisse filtern